empagliflozin/linagliptin vs lithium
According to this portal's Publishing Organization, this page was last reviewed in August 2026 against our methodology. Figures and extracts on this site, including tables above 1,000 rows when the corpus is that large, are the publisher's responsibility.
Side-by-side comparison of empagliflozin/linagliptin and lithium. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
minor Known Drug Interaction
Lithium Clinical Impact Concomitant use of an SGLT2 inhibitor with lithium may decrease serum lithium concentrations. Intervention Monitor serum lithium concentration more frequently during TRIJARDY XR initiation and dosage changes.
Glyxambi
Lithobid, Eskalith
Glyxambi is a drug that combines three medicines to help lower blood sugar in adults with type 2 diabetes. It can also lower the risk of death from heart problems in those with both type 2 diabetes and heart disease.
Lithium is a mood stabilizer medicine. It helps to balance mood swings.
Glyxambi is used to improve blood sugar control in adults with type 2 diabetes. It should be used along with diet and exercise. Glyxambi can also help lower the risk of death caused by heart problems if you have both type 2 diabetes and heart disease. It is not for people with type 1 diabetes.
Lithium is used to treat bipolar disorder. Bipolar disorder causes unusual shifts in mood, energy, activity levels, and concentration. Lithium helps to control the extreme highs (mania) and lows (depression) of this condition.
Glyxambi works in three ways to lower blood sugar. Empagliflozin helps your kidneys remove sugar from your blood through urine. Linagliptin helps your body release more insulin after meals. Metformin helps to decrease the amount of sugar your liver makes and helps your body use insulin better.
Lithium affects the flow of sodium in nerve and muscle cells in the body. This helps to stabilize your mood. It may also affect other chemical messenger systems in the brain.
- • Upper respiratory infection (like a cold)
- • Urinary tract infection
- • Runny or stuffy nose
- • Diarrhea
- • Constipation
- • Tremor (shaking)
- • Nausea
- • Increased weight
- • Fatigue (feeling tired)
- • Vomiting
- Increased blood sugar 146
- Diabetic ketoacidosis 144
- Feeling sick to your stomach 102
- Fungal infection 92
- Weight loss 86
- Toxicity To Various Agents 2,179
- Drug Interaction 1,526
- Tremor 1,462
- Nausea 1,344
- Weight Increased 1,153
Glyxambi contains metformin, which can cause a serious side effect called lactic acidosis. Lactic acidosis is a buildup of lactic acid in the blood. It can be life-threatening. Get medical help right away if you have symptoms like feeling very weak, tired, or uncomfortable; unusual muscle pain; trouble breathing; stomach pain with nausea and vomiting; feeling cold, especially in your arms and legs; feeling dizzy or lightheaded; or a sudden change in your heartbeat.
Lithium levels in your blood need to be monitored closely by your doctor. Too much lithium can be toxic and cause serious side effects. Make sure to attend all scheduled blood tests.
Glyxambi is not recommended during the second and third trimesters of pregnancy due to potential harm to the baby's kidneys. It is also not recommended while breastfeeding. Talk to your doctor if you are pregnant, plan to become pregnant, or are breastfeeding.
Lithium can harm your unborn baby. Talk to your doctor if you are pregnant or plan to become pregnant. Lithium can pass into breast milk and may harm a nursing infant. Talk to your doctor about the best way to feed your baby if you are taking lithium.
How to Read This empagliflozin/linagliptin vs lithium Comparison
empagliflozin/linagliptin is classified in the SGLT2 / DPP-4 Combination drug class, while lithium sits within the Mood Stabilizer class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, empagliflozin/linagliptin has 570 submissions while lithium has 7,664. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. These two drugs have a known minor interaction flagged in FDA labeling, attributed to this diabetes medicine can cause your kidneys to remove lithium from your body more quickly. this may lower the amount of lithium in your blood and make it work less effectively.. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot represent individual circumstances. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This registry does not provide medical, treatment, substitution, or medication-change directions for empagliflozin/linagliptin or lithium.
Registry boundary: This comparison displays source-record fields and does not provide individualized medical direction.